Haleon plc (NYSE:HLN – Get Rating)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $8.17, but opened at $8.34. Haleon shares last traded at $8.40, with a volume of 952,817 shares.
Analyst Ratings Changes
Several equities research analysts have commented on HLN shares. Sanford C. Bernstein started coverage on Haleon in a research note on Tuesday. They set an “outperform” rating for the company. Investec started coverage on Haleon in a research report on Thursday, February 23rd. They issued a “sell” rating for the company. Barclays upped their price target on Haleon from GBX 360 ($4.47) to GBX 364 ($4.52) in a research report on Tuesday, January 31st. Finally, Morgan Stanley upgraded Haleon from an “equal weight” rating to an “overweight” rating in a research report on Friday, January 6th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $364.00.
Haleon Stock Performance
The business has a 50 day simple moving average of $8.04 and a 200 day simple moving average of $7.32.
Haleon Dividend Announcement
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in HLN. New England Research & Management Inc. acquired a new position in Haleon during the third quarter worth $181,000. Stonebridge Capital Management Inc. acquired a new stake in shares of Haleon in the third quarter valued at $68,000. DAVENPORT & Co LLC acquired a new stake in shares of Haleon in the third quarter valued at $181,000. Jacobs & Co. CA acquired a new stake in shares of Haleon in the third quarter valued at $1,027,000. Finally, Bonness Enterprises Inc. acquired a new stake in shares of Haleon in the third quarter valued at $403,000. 6.67% of the stock is currently owned by institutional investors and hedge funds.
About Haleon
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.
Featured Articles
- Get a free copy of the StockNews.com research report on Haleon (HLN)
- Penny Stock Wag! Group Co. Has Solid Sell-Side Support
- Staples Stocks Get Lift From Conagra Results, New Highs In Sight
- SGH Bottomed, But Can It Reverse And Move Higher?
- Is Pinterest Showing Signs of an Improving Ad Market?
- At 3x Earnings, Avis Budget Is Worth Taking for a Spin
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
